Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)
Individuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease.
Most of them are females of childbearing age. Currently, there is no proven effective
therapy and the prognosis is variable. This study is designed to (a) define the clinical
course of the disease and (b) elucidate the pathogenesis of the disease at the cellular and
molecular levels, in order to develop more effective therapy. To accomplish this, we intend
to identify the proteins and genes that contribute to the process of lung destruction in
Joel Moss, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike
|Bethesda, Maryland 20892